Incyte to Present Phase 3 Oncology Data at ESMO Congress
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Incyte announced it will present new clinical information from its oncology portfolio at the European Society of Medical Oncology (ESMO) Congress in Madrid. The presentation will cover two investigational therapies: INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFßR2×PD-1 bispecific antibody. Both therapies are currently being evaluated in ongoing Phase 3 programs.
From finanznachrichten.de
Why it matters
The findings presented at ESMO are expected to provide new clinical insights and inform Incyte's registrational development programs. The success of these novel approaches is relevant to Incyte's strategic partnerships, including the co-development agreement with Syndax Pharmaceuticals.
From finanznachrichten.de
Who's involved
- IncyteAmerican pharmaceutical company presenting new clinical information on its oncology portfolio.
- Syndax PharmaceuticalsCompany maintaining an exclusive worldwide co-development and co-commercialization partnership with Incyte.
- FDARegulatory body whose approvals fundamentally depend on Incyte's drug pipeline.
- QiagenCompany maintaining a strategic partnership with Incyte for companion diagnostics.